Patents by Inventor Zhi-Liang Chu

Zhi-Liang Chu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of using GPR119 to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
    Patent number: 7838254
    Abstract: The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: November 23, 2010
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Zhi-Liang Chu, James N Leonard, Robert M Jones
  • COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL
    Publication number: 20100291589
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: November 2, 2009
    Publication date: November 18, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Hussien A. Al-Shamma, Robert M. Jones
  • Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
    Patent number: 7833730
    Abstract: The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: November 16, 2010
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Zhi-Liang Chu, James N. Leonard
  • COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL
    Publication number: 20100286153
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: November 2, 2009
    Publication date: November 11, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Hussien A. Al-Shamma, Robert M. Jones
  • COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL
    Publication number: 20100286172
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: November 2, 2009
    Publication date: November 11, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Hussien A. Al-Shamma, Robert M. Jones
  • COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL
    Publication number: 20100286111
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: November 2, 2009
    Publication date: November 11, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Hussien A. Al-Shamma, Robert M. Jones
  • COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL
    Publication number: 20100285495
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: November 2, 2009
    Publication date: November 11, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Hussien A. Al-Shamma, Robert M. Jones
  • COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL
    Publication number: 20100286168
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: November 2, 2009
    Publication date: November 11, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Hussien A. Al-Shamma, Robert M. Jones
  • COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL
    Publication number: 20100285494
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: November 2, 2009
    Publication date: November 11, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Hussien A. Al-Shamma, Robert M. Jones
  • GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto
    Patent number: 7816364
    Abstract: The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: October 19, 2010
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Zhi-Liang Chu, James N. Leonard, Juerg Lehmann, Robert M. Jones
  • Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
    Patent number: 7803753
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: September 28, 2010
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Zhi-Liang Chu, James N. Leonard, Hussien A. Al-Shamma, Robert M. Jones
  • Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
    Patent number: 7803754
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: September 28, 2010
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Zhi-Liang Chu, James N. Leonard, Hussien A. Al-Shamma, Robert M. Jones
  • METHODS OF USING A G PROTEIN-COUPLED RECEPTOR TO IDENTIFY PEPTIDE YY (PYY) SECRETAGOGUES AND COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MODULATED BY PYY
    Publication number: 20100210666
    Abstract: The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.
    Type: Application
    Filed: April 22, 2010
    Publication date: August 19, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Robert M. Jones
  • METHODS OF USING GPR119 TO IDENTIFY COMPOUNDS USEFUL FOR INCREASING BONE MASS IN AN INDIVIDUAL
    Publication number: 20100203577
    Abstract: The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual.
    Type: Application
    Filed: February 4, 2010
    Publication date: August 12, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard
  • METHODS OF USING A G PROTEIN-COUPLED RECEPTOR TO IDENTIFY PEPTIDE YY (PYY) SECRETAGOGUES AND COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MODULATED BY PYY
    Publication number: 20100203556
    Abstract: The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.
    Type: Application
    Filed: April 22, 2010
    Publication date: August 12, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Robert M. Jones
  • METHODS OF USING GPR119 TO IDENTIFY COMPOUNDS USEFUL FOR INCREASING BONE MASS IN AN INDIVIDUAL
    Publication number: 20100203038
    Abstract: The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual.
    Type: Application
    Filed: February 4, 2010
    Publication date: August 12, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard
  • METHODS OF USING GPR119 TO IDENTIFY COMPOUNDS USEFUL FOR INCREASING BONE MASS IN AN INDIVIDUAL
    Publication number: 20100203037
    Abstract: The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual.
    Type: Application
    Filed: February 4, 2010
    Publication date: August 12, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard
  • GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto
    Publication number: 20100190750
    Abstract: The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.
    Type: Application
    Filed: April 1, 2010
    Publication date: July 29, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Juerg Lehmann, Robert M. Jones
  • COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL
    Publication number: 20100137293
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: October 30, 2009
    Publication date: June 3, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Hussein A. Al-Shamma, Robert M. Jones
  • Methods of using gpr 119 receptor to identify compounds useful for increasing bone mass in an individual
    Publication number: 20100068700
    Abstract: The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual.
    Type: Application
    Filed: April 10, 2007
    Publication date: March 18, 2010
    Inventors: Zhi-Liang Chu, James M. Leonard